SkinBioTherapeutics PLC

SkinBioTherapeutics 'getting more confident' as it hits half-way point in human studies

Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (AIM:SBTX), tells Proactive London's Andrew Scott there've been no safety or compliance concerns with people taking part in a test of the company’s skin cream.

Half the 120 volunteers have been through the trial process with the study set to complete as expected during this quarter.

Data yielded will be assessed to determine the effectiveness of the group’s SkinBiotix technology and whether it retains the same beneficial property of improving skin health when in a cream formulation.

Quick facts: SkinBioTherapeutics PLC

Price: £0.16

Market: AIM
Market Cap: £20.49 m


SkinBioTherapeutics' Cath O'Neill 'thrilled' with human study data for skin...

Dr Cath O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), speaks to Proactive's Andrew Scott after announcing the results from the company’s first human study of its SkinBiotix cream. The data has shown the product to be well tolerated and efficacious in certain age groups...

on 9/4/19

2 min read